Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients

Clinical Rheumatology

Volumn 21, Issue 6, 2002, Pages 457-461

  Refai, T M K ^a   Al Salem, I H ^a   Nkansa Dwamena, D ^a   Al Salem, M H ^b  

^a AL AMIRI HOSPITAL   (Kuwait)

^b FARWANIYA HOSPITAL   (Kuwait)

Author keywords

Homocystein; Systemic lupus erythematosus; Thrombosis

Indexed keywords

CARDIOLIPIN ANTIBODY; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; THROMBOPLASTIN;

ADULT; ARTICLE; CAROTID ARTERY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; KUWAIT; MALE; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TEACHING HOSPITAL; THROMBOSIS;

ADULT; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KUWAIT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RISK FACTORS; THROMBOSIS;

EID: 0036871121     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100670200115     Document Type: Article

References (21)

1. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosis. Long-term followup of an inception cohort. Arthritis Rheum 1995;38:1492-9.
2. Jacobsen S, Petersen J, Ullman S et al. A multicenter study of 513 Danish patients with systemic lupus erythematosus. II Disease mortality and clinical factors of prognostic value. Clin Rheumatol 1998;17:478-84.
3. Zizic TM, Marcoux C, Hungerford DS, Dansereau JV, Stevens MB. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med 1985;79:596-603.
4. Salafia CM, Starzyk K, Lopez-Zena J, Parke A. Fetal losses and other obstetric manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The antiphospholipid syndrome. Boca Raton, Bobstern, 1996:117-31.
5. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
6. Clarke R, Daly L, Robinson K et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:149-55.
7. Harper AE, Benevenge NJ, Wohlheuter RM. Effects of ingestion of disproportionate amounts of amino acids. Physiol Rev 1970;50:428-558.
8. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-16.
9. Tsai JC, Perrella MA, Yashizum M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91:6369-73.
10. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In: Francis RBJ, ed. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker, 1989:182-236.
11. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-8.
12. Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995;332:286-91.
13. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shapr AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
14. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
15. Yoo JH, Chung Ch S, Kang SS. Relation of plasma homocysteine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478-83.
16. Petri M, Roubenoff R, Dallal GE et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
17. Fijnheer R, Roest M, Haas FJ et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematous: A retrospective cohort study. J. Rheumatol 1998;25:1737-42.
18. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinaemia in an elderly poplation. JAMA 1993;270:2693-8.
19. Brattstrom L. Vitamms as homocysteine-lowering agents. J Nutr 1996;126:1276-80.
20. Ubbink JB, Vermaak WJ, van der Merwe A et al. Vitamin requirements for the treatment of hyperhomocysteinaemia in humans. J Nutr 1994;124:1927-33.
21. Kittner SJ, Giles WH, Macko RF et al. Homocysteine and risk of cerebral infarction in a biracial population: the stroke prevention in young women study. Stroke 1999;30:1554-60.